News

Task Force Opening: Shared Molecular Etiologies Underlying Multiple Rare Diseases

The Interdisciplinary Scientific Committee (ISC) is establishing a Task Force on Shared Molecular Etiologies Underlying Multiple Rare Diseases aiming to address and document the existing challenges in adapting the basket trial approach used in molecularly targeted oncology clinical trials to drugs targeting shared molecular etiologies underlying multiple rare diseases. The Task Force will identify how […]

Read More

Task Force Opening: Shared Molecular Etiologies Underlying Multiple Rare Diseases

The Interdisciplinary Scientific Committee (ISC) is establishing a Task Force on Shared Molecular Etiologies Underlying Multiple Rare Diseases aiming to address and document the existing challenges in adapting the basket trial approach used in molecularly targeted oncology clinical trials to drugs targeting shared molecular etiologies underlying multiple rare diseases. The Task Force will identify how […]

Read More

Task Force Opening: Integrating New Technologies for the Diagnosis of Rare Diseases

The Diagnostics Scientific Committee (DSC) is establishing a Task Force on the Integration of New Technologies for the Diagnosis of Rare Diseases. This activity proposes to identify the most clinically beneficial combination(s) of metabolomic and genomic tests coupled with artificial intelligence methodologies, which would then be prioritized for development of diagnostic standards. This will ultimately […]

Read More

Task Force Opening: Integrating New Technologies for the Diagnosis of Rare Diseases

The Diagnostics Scientific Committee (DSC) is establishing a Task Force on the Integration of New Technologies for the Diagnosis of Rare Diseases. This activity proposes to identify the most clinically beneficial combination(s) of metabolomic and genomic tests coupled with artificial intelligence methodologies, which would then be prioritized for development of diagnostic standards. This will ultimately […]

Read More

FDA Rare Disease Day Virtual Public Meeting

We are pleased to announce that FDA will be holding a virtual public meeting on Friday, March 5, 2021, from 9:00 a.m. to 4:00 p.m. EST to highlight strategies to support rare disease product development. Please visit the public meeting page to register for the event, https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/public-meeting-fda-rare-disease-day-2021-03052021-03052021 To learn more about other activities relevant to rare diseases […]

Read More

FDA Rare Disease Day Virtual Public Meeting

We are pleased to announce that FDA will be holding a virtual public meeting on Friday, March 5, 2021, from 9:00 a.m. to 4:00 p.m. EST to highlight strategies to support rare disease product development. Please visit the public meeting page to register for the event, https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/public-meeting-fda-rare-disease-day-2021-03052021-03052021 To learn more about other activities relevant to rare diseases […]

Read More

The IRDiRC Conference and RE(ACT) Congress moves online.

November 9th 2020 The International Rare Diseases Research Consortium (IRDiRC) and The BLACKSWAN Foundation alongside with the European Joint Programme on Rare Diseases (EJP RD) are hosting a joint online event IRDiRC Conference and RE(ACT) Congress 2021 from 13th to 15th January. This joint online event will continue the IRDiRC Conference series (4th edition) and the RE(ACT) Congress series (6th edition). […]

Read More